{"product_id":"straumann-swot-analysis","title":"Straumann Holding SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eStraumann’s leadership in premium dental implants, strong R\u0026amp;D pipeline, and global service network position it well against regulatory and competitive pressures, while exposure to cyclical dental spending and supply-chain risks warrant caution; uncover the full strategic implications and quantitative assessments in our complete SWOT analysis—purchase the editable Word + Excel package for investor-ready insights, actionable recommendations, and presentation-ready material.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Global Market Share in Dental Implants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of end-2025, Straumann Holding leads the global dental implant market with roughly 32% market share across premium and value segments and CHF 2.45bn implant revenue in 2025, cementing dominance. Decades of clinical excellence and 2,300+ peer-reviewed studies underpin trust and premium pricing. Massive scale gives global distribution in 100+ countries, top brand recognition, and the firepower—CHF 180m R\u0026amp;D spend in 2025—to fund large trials and product development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Integrated Digital Workflow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStraumann has built a unified digital ecosystem—intraoral scanners, CAD\/CAM software, and 3D printing—letting clinicians handle diagnosis to final restoration in one workflow; in 2024 Straumann Digital Solutions revenue rose ~18% to CHF 540m, showing adoption. This integration cuts chair time, boosts surgical accuracy, and raises practitioner switching costs, supporting higher margin recurring sales and stronger customer loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Multi-Brand Portfolio Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStraumann uses a multi-brand approach to cover premium and value segments without diluting its core premium name; subsidiaries and partners such as Medentika and Anthogyr serve the value segment, which grew ~8–10% annually in 2024, helping Straumann capture price-sensitive markets while preserving ~60% gross margin on premium implants reported in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnmatched Investment in Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpstraumann sustained r spend of revenue in on chf sales surface tech like slactive and roxolid alloys delivering faster osseointegration higher strength implants fueling a steady stream patent-protected launches.\u003e\n\u003cpthe scientific lead and patent portfolio create high barriers to entry limiting price pressure from smaller rivals generics while supporting premium asps better clinical outcomes.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend ~8.5% of revenue (2024)\u003c\/li\u003e\n\u003cli\u003eCHF 220m R\u0026amp;D in 2024\u003c\/li\u003e\n\u003cli\u003eKey tech: SLActive surface, Roxolid alloy\u003c\/li\u003e\n\u003cli\u003ePatents + clinical data = barrier to entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pstraumann\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Global Distribution and Education Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStraumann reaches over 100 countries with a direct presence in ~50 markets and reported 2024 sales of CHF 2.3 billion, giving it one of the deepest global commercial footprints in dental implants.\u003c\/p\u003e\n\u003cp\u003eThe group funds the International Team for Implantology (ITI), educating ~15,000 clinicians annually through courses and research, which strengthens clinician loyalty and product integration.\u003c\/p\u003e\n\u003cp\u003eThis education-to-sales pipeline boosts recurring revenue and premium implant adoption, supporting Straumann’s market share and pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePresence: \u0026gt;100 countries; direct in ~50\u003c\/li\u003e\n\u003cli\u003eRevenue 2024: CHF 2.3bn\u003c\/li\u003e\n\u003cli\u003eITI trainees: ~15,000\/year\u003c\/li\u003e\n\u003cli\u003eEffect: higher clinician loyalty, recurring sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStraumann: Global implant leader—32% share, CHF2.45bn implants, digital growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStraumann dominates global implants (~32% share; CHF 2.45bn implant revenue 2025), strong R\u0026amp;D (CHF 220–180m range; ~8.5% revenue), integrated digital ecosystem (Digital Solutions CHF 540m 2024, +18%), multi-brand coverage preserves premium margins (~60% gross on premium), global reach \u0026gt;100 countries, ITI trains ~15,000 clinicians\/year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e~32%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImplant rev\u003c\/td\u003e\n\u003ctd\u003eCHF 2.45bn (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCHF 220m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital rev\u003c\/td\u003e\n\u003ctd\u003eCHF 540m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Straumann Holding’s internal strengths and weaknesses and the external opportunities and threats shaping its competitive position in the dental implant and orthodontics markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Straumann Holding SWOT snapshot for rapid strategic alignment and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Discretionary Consumer Spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of Straumann Holding’s revenue comes from elective dental implants and prosthetics often paid out-of-pocket; in 2024 implants \u0026amp; restorative products made roughly 60% of group sales (Straumann 2024 annual report).\u003c\/p\u003e\n\u003cp\u003eWhen inflation hit 7% in parts of Europe in 2022–23 and GDP contracted in select markets, surveys showed elective dental demand fell 10–20%, raising revenue volatility for Straumann versus essential-care peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Operational Costs and Currency Exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith headquarters and major plants in Switzerland, Straumann bears a high labor and operating cost base; Swiss manufacturing wages average ~CHF 95,000\/year versus EU peers around CHF 55,000, raising COGS and SG\u0026amp;A pressure. The strong Swiss franc—up ~6% vs EUR and 3% vs USD in 2024—eroded reported 2024 EBIT by an estimated CHF 40–60m and hurt export pricing. Ongoing efficiency drives and automation investments (CHF 120m capex guidance 2025) are needed to protect operating margins and remain competitive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexities in Integrating Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe aggressive expansion into orthodontics and digital dentistry via 18 acquisitions since 2016 has layered Straumann Holding with a complex org chart; integrating varied corporate cultures and legacy IT stacks remains difficult.\u003c\/p\u003e\n\u003cp\u003eManagement reported EUR 1.95bn M\u0026amp;A spend in 2023 and warned that integration slippage could cut expected synergies of ~EUR 120–150m by 2025. Any friction risks operational inefficiencies and slower revenue realization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on the Premium Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStraumann still earns roughly 60–65% of adjusted operating profit from premium dental implants and related prosthetics, making the group highly exposed if clinicians or patients shift to lower-cost options.\u003c\/p\u003e\n\u003cp\u003eTrading-down risks rose in 2024 as discount implant makers and value-focused chains pushed prices 15–25% lower in key markets, increasing price sensitivity.\u003c\/p\u003e\n\u003cp\u003eMaintaining the premium moat needs sustained marketing spend (Straumann spent ~CHF 300m on sales \u0026amp; marketing in 2024) and incremental R\u0026amp;D, which compresses margins if volume falls.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e~60–65% profit concentration\u003c\/li\u003e\n\u003cli\u003e2024 S\u0026amp;M ~CHF 300m\u003c\/li\u003e\n\u003cli\u003eDiscount rivals cut prices 15–25%\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Specialized Clinical Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStraumann’s advanced implant and digital-orthodontic systems need high technical skill from dental surgeons and lab technicians, limiting uptake where certified professionals are scarce; WHO data (2024) shows up to 60% dentist shortages in parts of Sub-Saharan Africa and Southeast Asia, creating regional bottlenecks.\u003c\/p\u003e\n\u003cp\u003eTraining programs raised Straumann’s 2024 selling, general \u0026amp; administrative expenses, contributing to an estimated incremental customer acquisition cost of ~€200–€400 per clinic and pressuring mid-term margins.\u003c\/p\u003e\n\u003cp\u003eMaintaining certification and post-sale support demands recurring investment, slowing scalable revenue growth for high-end product lines compared with commoditized implants.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-skill need limits market in 60% shortage regions\u003c\/li\u003e\n\u003cli\u003eTraining adds ~€200–€400 CAC per clinic (2024 est.)\u003c\/li\u003e\n\u003cli\u003eRecurring support raises OPEX and slows scaling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStraumann faces demand, FX and M\u0026amp;A strain as premium implants drive profit risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStraumann relies heavily on elective, premium implants—~60% of 2024 sales and ~60–65% of adjusted operating profit—making revenue sensitive to demand shocks and trading-down; discount rivals cut prices 15–25% in 2024. High Swiss labor costs (avg wage ~CHF 95,000) and a strong franc cut 2024 EBIT by ~CHF 40–60m, while EUR 1.95bn M\u0026amp;A since 2023 risks synergy slippage (~EUR 120–150m).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 implants share\u003c\/td\u003e\n\u003ctd\u003e~60% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. op profit concentration\u003c\/td\u003e\n\u003ctd\u003e60–65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwiss avg wage\u003c\/td\u003e\n\u003ctd\u003e~CHF 95,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX drag 2024\u003c\/td\u003e\n\u003ctd\u003eCHF 40–60m EBIT\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023–24 M\u0026amp;A spend\u003c\/td\u003e\n\u003ctd\u003eEUR 1.95bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected synergy risk\u003c\/td\u003e\n\u003ctd\u003eEUR 120–150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eStraumann Holding SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eThis is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752509583737,"sku":"straumann-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/straumann-swot-analysis.png?v=1772241843","url":"https:\/\/matrixbcg.com\/products\/straumann-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}